In early 2022, I recall seeing another shift in utilization from GLP-1s with less weight loss benefit (Victoza, Soliqua, Trulicity, etc.) to Ozempic and Mounjaro, creating a consolidation in usage that along with other factors likely led to minor rebate improvement but increased initial costs
If you consistently fall below this threshold, you are not succeeding at weight loss
[22] Metoclopramide (Reglan) works by promoting gastric emptying, theoretically counteracting the GLP-1 mechanism, but carries a boxed warning for tardive dyskinesia and should not be used for longer than 12 weeks except in rare circumstances
The GLP1 family of drugs is becoming larger, more effective and easier to use, Dr
Therefore, glucose status should be carefully evaluated prior to initiating tesamorelin treatment